Comparative postoperative outcomes of GGN-dominant vs single lesion lung adenocarcinomas.
Adenocarcinoma
Ground glass nodule
Ground glass opacity
Multiple primary lung cancers
Surgical treatment
Journal
Journal of cardiothoracic surgery
ISSN: 1749-8090
Titre abrégé: J Cardiothorac Surg
Pays: England
ID NLM: 101265113
Informations de publication
Date de publication:
22 Jun 2020
22 Jun 2020
Historique:
received:
07
05
2020
accepted:
15
06
2020
entrez:
24
6
2020
pubmed:
24
6
2020
medline:
18
11
2020
Statut:
epublish
Résumé
Multiple synchronous ground glass nodules (GGNs) are known to be malignant, however, they tend to progress slowly. Multiple synchronous lesions in the same patient which show different characteristics must be treated individually. This was a retrospective review of 34 lung adenocarcinoma patients with multiple synchronous GGNs in an Asian population. One hundred twenty-seven single lung adenocarcinoma patients were included for comparison purposes. The follow-up period was 5 years for all patients. The 5-year overall survival (OS) patients with multiple lesions did not differ from that of the patients with single lesions to a statistically significant extent (Single: 81.8% vs. Multiple: 88.2%, P = 0.3602). Dominant tumors (DTs) with a ground glass component and consolidation were divided into three categories based on the consolidation-to-tumor ratio on radiological imaging. No significant differences were observed among the three DT categories. Twenty-four patients had unresected GGNs, while a progression of the unresected GGN occurred in 10 of these cases. The OS and disease-free survival (DFS) curves of patients with and without GGN progression did not differ to a statistically significant extent (OS: 80% vs. 92.9%, P = 0.3870; DFS: 80% vs. 100%, P = 0.0977). The outcomes were best predicted by the stage of the DT. After surgery patients require a careful follow-up because unresected GGNs may show progression. At the same time, the increase in residual lesions and the appearance of new GGNs were not related to OS. The management of such patients should be determined according to the DT with the worst prognosis.
Sections du résumé
BACKGROUND
BACKGROUND
Multiple synchronous ground glass nodules (GGNs) are known to be malignant, however, they tend to progress slowly. Multiple synchronous lesions in the same patient which show different characteristics must be treated individually.
METHODS
METHODS
This was a retrospective review of 34 lung adenocarcinoma patients with multiple synchronous GGNs in an Asian population. One hundred twenty-seven single lung adenocarcinoma patients were included for comparison purposes. The follow-up period was 5 years for all patients.
RESULTS
RESULTS
The 5-year overall survival (OS) patients with multiple lesions did not differ from that of the patients with single lesions to a statistically significant extent (Single: 81.8% vs. Multiple: 88.2%, P = 0.3602). Dominant tumors (DTs) with a ground glass component and consolidation were divided into three categories based on the consolidation-to-tumor ratio on radiological imaging. No significant differences were observed among the three DT categories. Twenty-four patients had unresected GGNs, while a progression of the unresected GGN occurred in 10 of these cases. The OS and disease-free survival (DFS) curves of patients with and without GGN progression did not differ to a statistically significant extent (OS: 80% vs. 92.9%, P = 0.3870; DFS: 80% vs. 100%, P = 0.0977).
CONCLUSIONS
CONCLUSIONS
The outcomes were best predicted by the stage of the DT. After surgery patients require a careful follow-up because unresected GGNs may show progression. At the same time, the increase in residual lesions and the appearance of new GGNs were not related to OS. The management of such patients should be determined according to the DT with the worst prognosis.
Identifiants
pubmed: 32571419
doi: 10.1186/s13019-020-01196-x
pii: 10.1186/s13019-020-01196-x
pmc: PMC7310249
doi:
Types de publication
Comparative Study
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
149Références
N Engl J Med. 2011 Aug 4;365(5):395-409
pubmed: 21714641
N Engl J Med. 2013 May 23;368(21):1980-91
pubmed: 23697514
J Thorac Imaging. 2015 Mar;30(2):108-14
pubmed: 25658475
AJR Am J Roentgenol. 2000 Mar;174(3):763-8
pubmed: 10701622
Thorac Cancer. 2015 Jul;6(4):385-9
pubmed: 26273391
Lung Cancer. 2015 May;88(2):174-80
pubmed: 25758554
Br J Radiol. 2000 Dec;73(876):1252-9
pubmed: 11205667
Eur J Cardiothorac Surg. 2017 Nov 1;52(5):848-851
pubmed: 28977403
Thorax. 2017 Jan;72(1):48-56
pubmed: 27364640
J Thorac Oncol. 2013 Mar;8(3):309-14
pubmed: 23399958
Ann Thorac Surg. 2013 Aug;96(2):411-8
pubmed: 23806231
Lung Cancer. 2017 Nov;113:7-13
pubmed: 29110852
J Thorac Oncol. 2015 May;10(5):778-783
pubmed: 25629635
Eur J Cardiothorac Surg. 2016 Nov;50(5):909-913
pubmed: 27032467
J Thorac Oncol. 2018 Nov;13(11):1776-1783
pubmed: 30121391
Ann Thorac Surg. 2018 Nov;106(5):1504-1511
pubmed: 30086278
J Thorac Cardiovasc Surg. 2017 Dec;154(6):2092-2099.e2
pubmed: 28863952
Lung Cancer. 2018 Sep;123:52-59
pubmed: 30089595
J Thorac Dis. 2018 Aug;10(8):4838-4848
pubmed: 30233857